MRKMerck Sharp & Dohme LLCFinished
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
Carcinoma, Non-Small-Cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 100 (final count)
- Started
- Jan 7, 2021
- Main results expected
- Oct 31, 2025
- Fully finished
- Oct 31, 2025
- Results posted
- Oct 29, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Measured over: Up to approximately 56 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04165083 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC